FDA Calendar for Dendreon Corporation (DNDN)

| Register (free)
Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that improve cancer treatment options for patients. Dendreon’s most advanced product candidate is Provenge (sipuleucel-T), an active cellular immunotherapy that has completed two Phase III trials for the treatment of asymptomatic, metastatic, androgen-independent prostate cancer.


Drug Pipeline

Drug NameType Of DrugFDA StatusDrug Phase
Provenge Cancer Pending DecisionNDA


Events

No future events listed at this time, please check back later.
1 past event(s) found. Click here to view them.

Add New Event

In order to write a comment you must first login.

Login or Register (for free!)

Add Event

DNDN

$14.17
0.23 +1.65%
2/3/2012 4:00:00 PM

Sponsors

Other Links